Edaravone and dexborneol concentrate for solution for injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Medicine type
- Chemical medicine
- Therapeutic area
- Neurology
- Indications recorded in the public source
- For improvement of neurological symptoms, activities of daily living and functional impairment caused by acute ischemic stroke.
- Indication source and scope
- Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- Prescribing-information limitations
- Indications checked against an official public submission. The full original prescribing information is still unavailable.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to newly occurring acute ischemic stroke when treatment starts within 48 hours of onset; reimbursement is limited to 14 days.
- Insurance period
- 2025-01-01 to 2026-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cnpharm.com/upload/resources/file/2021/06/21/92867.docx
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.nhsa.gov.cn/attach/Ypsn2024/YPSN202400162/YPSN202400162.pdf
Open the interactive record, public price references and discussions